

# A multicentre randomised double-blind placebo-controlled study comparing two regimens of combination induction therapy in early disease-modifying anti-rheumatic drug naïve rheumatoid arthritis

**Submission date**

25/10/2006

**Recruitment status**

No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**

30/04/2007

**Overall study status**

Completed

☐ Statistical analysis plan

☒ Results

**Last Edited**

19/09/2016

**Condition category**

Musculoskeletal Diseases

☐ Individual participant data

**Plain English summary of protocol**

Not provided at time of registration

## Contact information

**Type(s)**

Scientific

**Contact name**

Prof Paul Emery

**Contact details**

c/o James Goulding  
Academic Unit of Musculoskeletal Disease  
2nd Floor, Chapel Allerton Hospital  
Chapeltown Road  
Leeds  
United Kingdom  
LS7 4SA  
+44 (0)113 392 3043  
J.T.R.Goulding@leeds.ac.uk

## Additional identifiers

EudraCT/CTIS number

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

RR05/7092

## **Study information**

### **Scientific Title**

A multicentre randomised double-blind placebo-controlled study comparing two regimens of combination induction therapy in early disease-modifying anti-rheumatic drug naïve rheumatoid arthritis

### **Acronym**

IDEA (Infliximab as inDuction therapy in Early rheumatoid Arthritis)

### **Study objectives**

To compare the efficacy of biologic therapy (infliximab) as induction therapy against current best practice therapy: early introduction of methotrexate in combination with steroid induction therapy and dose modification according to pre-defined disease activity measures.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Northern and Yorkshire Multi-Centre Research Ethics Committee, 06/04/2006, ref: 05/MRE03/85

### **Study design**

Multicentre double-blind placebo-controlled randomised clinical trial for 6 months followed by open-label observation period of treatment strategy

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet

### **Health condition(s) or problem(s) studied**

Early rheumatoid arthritis

## **Interventions**

Infliximab arm:

1. Methotrexate (10 mg, increasing to 20 mg by six weeks) orally once a week for the treatment period of the trial (18 months)
2. Infliximab (3 mg/kg) intravenous (IV) infusion at baseline, week two, week six and then eight-weekly for the treatment period of the trial (18 months)

Steroid/placebo arm:

1. Methotrexate (10 mg, increasing to 20 mg by six weeks) orally once a week for the treatment period of the trial (18 months)
2. Methylprednisolone (250 mg IV infusion at baseline)
3. Placebo (250 ml 9 mg/l NaCl at weeks two, six, 14 and 22)

N.B.: These regimens are subject to modification depending upon patient response.

## **Intervention Type**

Drug

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

Infliximab, methotrexate, steroid

## **Primary outcome measure**

Change in Sharpe van Der Heijde score at 50 weeks.

## **Secondary outcome measures**

Secondary outcomes in this study include changes in clinical response over 18 months as measured by:

1. The number of patients having a major clinical response (DAS less than 1.6 maintained for six months)
2. The change in Sharpe van Der Heijde scores between baseline and 26 and 78 weeks
3. The number of patients in clinical remission (DAS less than 1.6) at 78 weeks
4. The number of patients in clinical remission (DAS less than 1.6) at 78 weeks, no longer on infliximab/placebo infusions
5. The number of patients in clinical remission (DAS less than 1.6) at 26 weeks
6. Rheumatoid Arthritis Quality of Life Questionnaire (RA QoL)
7. Health Assessment Questionnaire
8. Immunogenetic studies to predict long-term immune response
9. Immune phenotyping (flow cytometry) and assessment of immune effector and regulatory functions
10. Assessment of serum and plasma markers to predict response to therapy and vascular function

## **Overall study start date**

26/09/2006

## **Completion date**

30/09/2007

# Eligibility

## Key inclusion criteria

1. Men and women 18 to 80 years of age
2. Fulfil 1987 American College of Rheumatology (ACR) Criteria for rheumatoid arthritis (RA)
3. Symptoms of more than three months and less than 12 months duration
4. Men and women must use adequate birth control measures (e.g., abstinence, oral contraceptives, intra-uterine device, barrier method with spermicide, or surgical sterilisation) for the duration of the study and should continue such precautions for six months after receiving the last infusion or dose of methotrexate
5. The patient must be able to adhere to the study visit schedule and other protocol requirements
6. The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures
7. Must have a chest radiograph within three months prior to first treatment dose with no evidence of malignancy, infection or fibrosis
8. Are considered eligible according to the tuberculosis (TB) eligibility assessment, screening, and early detection of reactivation rules defined in the protocol
9. Active disease as defined by Disease Activity Score (DAS) more than 2.4
10. Tumour necrotising factor (TNF) therapy naïve
11. Disease-modifying anti-rheumatic drug (DMARD) therapy naïve
12. Negative hepatitis B and C screening tests within three months prior to screening visit

## Participant type(s)

Patient

## Age group

Adult

## Lower age limit

18 Years

## Upper age limit

80 Years

## Sex

Both

## Target number of participants

112

## Key exclusion criteria

1. Women who are pregnant, nursing, or men or women planning pregnancy within 24 months after screening (i.e., approximately six months following last study medications)
2. Use of any investigational (unlicensed) drug within one month prior to screening or within five half-lives of the investigational agent, whichever is longer
3. Previous or current treatment with any other therapeutic agent targeted at reducing TNF (e.g., pentoxifylline, thalidomide, etanercept, infliximab, adalimumab etc.)
4. Prior treatment with any DMARD
5. Serious infections (such as pneumonia or pyelonephritis) in the previous three months. Less

serious infections (such as acute upper respiratory tract infection [colds] or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator

6. Documented human immunodeficiency virus (HIV) infection

7. Hepatitis B or hepatitis C serology positive (must be checked within three months prior to screening)

8. Are considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules defined in the protocol

9. Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, *Pneumocystis carinii*, aspergillosis, histoplasmosis, or mycobacteria other than TB) within six months prior to screening

10. Significant haematological or biochemical abnormality:

10.1. Haemoglobin less than or equal to 8.5 g/dL

10.2. White blood cells (WBC) less than or equal to  $3.5 \times 10^9/L$

10.3. Neutrophils less than or equal to  $1.5 \times 10^9/L$

10.4. Platelets less than or equal to  $100 \times 10^9/L$

10.5. Alanine aminotransferase (ALT) more than two times upper limit of normal (ULN) for the laboratory conducting the test

10.6. Creatinine more than 1.5 times ULN for the laboratory conducting the test

11. Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease (including demyelinating diseases such as multiple sclerosis)

12. Concomitant congestive heart failure, including medically controlled asymptomatic patients

13. Presence of a transplanted organ (with the exception of a corneal transplant more than three months prior to screening)

14. Malignancy within the past five years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence)

15. History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly

16. Known recent substance abuse (drug or alcohol)

17. Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period

18. Have a chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of TB as described in the protocol

19. Have a positive Mantoux test or evidence of active TB infection, or recent close contact with an individual with active TB

20. Previous oral, intramuscular (IM), intra-arterial (IA) or intravenous (IV) corticosteroids within one month

21. Receiving treatment with anakinra

22. Contraindications to methotrexate, infliximab or steroids

**Date of first enrolment**

26/09/2006

**Date of final enrolment**

30/09/2007

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Chapel Allerton Hospital**

Leeds

United Kingdom

LS7 4SA

## **Sponsor information**

**Organisation**

University of Leeds (UK)

**Sponsor details**

c/o Johnathan Gower

Senior Research Manager

Faculty of Medicine and Health, Room 7.11

Level 7 - Worsley Building

Clarendon Way

Leeds

England

United Kingdom

LS2 9NL

+44 (0)113 343 3264

j.gower@leeds.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.leeds.ac.uk/>

**ROR**

<https://ror.org/024mrxd33>

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/01/2014		Yes	No
<a href="#">Results article</a>	results	01/12/2016		Yes	No